{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:24:53Z","timestamp":1787754293176,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-selective inhibitors of cholinesterases (ChEs) are clinically used for treatment of <jats:italic>myasthenia gravis<\/jats:italic> (<jats:italic>MG<\/jats:italic>). While being generally safe, they cause numerous adverse effects including induction of hyperactivity of urinary bladder and intestines affecting quality of patients life. In this study we have compared two ChEs inhibitors, a newly synthesized compound C547 and clinically used pyridostigmine bromide, by their efficiency to reduce muscle weakness symptoms and ability to activate contractions of urinary bladder in a rat model of autoimmune <jats:italic>MG<\/jats:italic>. We found that at dose effectively reducing <jats:italic>MG<\/jats:italic> symptoms, C547 did not affect activity of rat urinary bladder. In contrast, at equipotent dose, pyridostigmine caused a significant increase in tonus and force of spontaneous contractions of bladder wall. We also found that this profile of ChEs inhibitors translates into the preparation of human urinary bladder. The difference in action observed for C547 and pyridostigmine we attribute to a high level of pharmacological selectivity of C547 in inhibiting acetylcholinesterase as compared to butyrylcholinesterase. These results raise reasonable hope that selective acetylcholinesterase inhibitors should show efficacy in treating <jats:italic>MG<\/jats:italic> in human patients with a significant reduction in adverse effects related to hyperactivation of smooth muscles.<\/jats:p>","DOI":"10.1038\/s41598-017-18307-9","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T12:09:29Z","timestamp":1515067769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment"],"prefix":"10.1038","volume":"8","author":[{"given":"Konstantin A.","family":"Petrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra D.","family":"Kharlamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana A.","family":"Lenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayrat R.","family":"Nurtdinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina E.","family":"Sitdykova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-6536","authenticated-orcid":false,"given":"Victor I.","family":"Ilyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Zueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny E.","family":"Nikolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"issue":"4","key":"18307_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1113\/jphysiol.1936.sp003371","volume":"86","author":"HH Dale","year":"1936","unstructured":"Dale, H. H., Feldberg, W. & Vogt, M. Release of acetylcholine at voluntary motor nerve endings. J Physiol. 86(4), 353\u2013380 (1936).","journal-title":"J Physiol."},{"key":"18307_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1126\/science.182.4109.293","volume":"182","author":"DM Fambrough","year":"1973","unstructured":"Fambrough, D. M., Drachman, D. B. & Satyamurti, S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science. 182, 293\u2013295 (1973).","journal-title":"Science."},{"key":"18307_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin, S. & Le Panse, R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J. Autoimmun. 52, 90\u2013100 (2014).","journal-title":"J. Autoimmun."},{"key":"18307_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/NDT.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza, R., Bonanno, S., Camera, G. & Antozzi, C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 7, 151\u201360 (2011).","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"1\u20133","key":"18307_CR5","first-page":"10","volume":"187","author":"I Silman","year":"2010","unstructured":"Silman, I. Acetylcholinesterase: from 3D structure to function. Chem Biol Interact. 187(1\u20133), 10\u201322 (2010).","journal-title":"Chem Biol Interact."},{"key":"18307_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/mus.20935","volume":"37","author":"AR Punga","year":"2008","unstructured":"Punga, A. R., Sawada, M. & Stalberg, E. V. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve. 37, 300\u2013307 (2008).","journal-title":"Muscle Nerve."},{"issue":"2","key":"18307_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1590\/S0100-879X2010005000001","volume":"43","author":"LI Zimerman","year":"2010","unstructured":"Zimerman, L. I. Acute electrophysiologic consequences of pyridostigmine inhibition of cholinesterase in humans. Braz J Med Biol Res. 43(2), 211\u2013216 (2010).","journal-title":"Braz J Med Biol Res."},{"key":"18307_CR8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1476-5381.2011.01211.x","volume":"163","author":"KA Petrov","year":"2011","unstructured":"Petrov, K. A. et al. Different sensitivities of rat skeletal muscles and brain to novel anti-cholinesterase agents, alkylammonium derivatives of 6-methyluracil (ADEMS). Br. J. Pharmacol. 163, 732\u2013744 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"18307_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/FJC.0b013e31819867d1","volume":"53","author":"DV Abramochkin","year":"2009","unstructured":"Abramochkin, D. V. et al. Mechanisms of cardiac muscle insensitivity to a novel acetylcholinesterase inhibitor C-547. J Cardiovasc Pharmacol. 53, 162\u2013166 (2009).","journal-title":"J Cardiovasc Pharmacol."},{"key":"18307_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1039\/C4MD00225C","volume":"5","author":"VE Semenov","year":"2014","unstructured":"Semenov, V. E. et al. Macrocyclic derivatives of 6-methyluracil as ligands of the peripheral anionic site of acetylcholinesterase. MedChemComm. 5, 1729\u20131735 (2014).","journal-title":"MedChemComm."},{"issue":"11","key":"18307_CR11","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/cmdc.201500334","volume":"10","author":"VE Semenov","year":"2015","unstructured":"Semenov, V. E. et al. 6-Methyluracil derivatives as bifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. ChemMedChem. 10(11), 1863\u20131874 (2015).","journal-title":"ChemMedChem."},{"key":"18307_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.abb.2016.02.010","volume":"593","author":"P Masson","year":"2016","unstructured":"Masson, P. & Lushchekina, S. V. Slow-binding inhibition of cholinesterases, pharmacological and toxicological relevance. Arch Biochem Biophys. 593, 60\u20138 (2016).","journal-title":"Arch Biochem Biophys."},{"issue":"9","key":"18307_CR13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1042\/BCJ20160084","volume":"473","author":"AD Kharlamova","year":"2016","unstructured":"Kharlamova, A. D. et al. Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment. Biochem J. 473(9), 1225\u20131236 (2016).","journal-title":"Biochem J."},{"key":"18307_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1196\/annals.1254.049","volume":"998","author":"F Baggi","year":"2003","unstructured":"Baggi, F. et al. Effect on T cell recognition and immunogenicity of alanine\u2010substituted peptides corresponding to 97\u2013116 sequence of the rat AChR \u03b1\u2010subunit. Ann. N. Y. Acad. Sci. 998, 395\u2013398 (2003).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"18307_CR15","doi-asserted-by":"publisher","first-page":"11870","DOI":"10.1523\/JNEUROSCI.0329-14.2014","volume":"34","author":"KA Petrov","year":"2014","unstructured":"Petrov, K. A. et al. Schwann cells sense and control acetylcholine spillover at the neuromuscular junction by \u03b17 nicotinic receptors and butyrylcholinesterase. J. Neurosci. 34, 11870\u201311883 (2014).","journal-title":"J. Neurosci."},{"key":"18307_CR16","first-page":"169","volume":"60","author":"AR Pachner","year":"1987","unstructured":"Pachner, A. R. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment. Yale J Biol Med. 60, 169\u2013177 (1987).","journal-title":"Yale J Biol Med."},{"key":"18307_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1113\/jphysiol.1973.sp010248","volume":"231","author":"B Katz","year":"1973","unstructured":"Katz, B. & Miledi, R. The binding of acetylcholine to receptors and its removal from the synaptic cleft. J Physiol. 231, 549\u201374 (1973).","journal-title":"J Physiol."},{"key":"18307_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00240-003-0326-1","volume":"31","author":"T Nakahara","year":"2003","unstructured":"Nakahara, T., Kubota, Y., Sakamoto, K. & Ishii, K. The role of cholinesterases in rat urinary bladder contractility. Urol Res. 31, 223\u2013226 (2003).","journal-title":"Urol Res."},{"issue":"26","key":"18307_CR19","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1016\/j.lfs.2005.04.028","volume":"77","author":"H Nagabukuro","year":"2005","unstructured":"Nagabukuro, H. & Doi, T. Differential effects of TAK-802, a selective acetylcholinesterase inhibitor, and carbamate acetylcholinesterase inhibitors on contraction of the detrusor smooth muscle of the guinea pig. Life Sci. 77(26), 3276\u201386 (2005).","journal-title":"Life Sci."},{"key":"18307_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1021\/jm010196t","volume":"45","author":"H Leader","year":"2002","unstructured":"Leader, H., Wolfe, A. D., Chiang, P. K. & Gordon, R. K. Pyridophens: binary pyridostigmine\u2212aprophen prodrugs with differential inhibition of acetylcholinesterase, butyrylcholinesterase, and muscarinic receptors. J Med Chem. 45, 902\u2013910 (2002).","journal-title":"J Med Chem."},{"issue":"4","key":"18307_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1476-5381.2009.00166.x","volume":"157","author":"VP Zagorodnyuk","year":"2009","unstructured":"Zagorodnyuk, V. P. et al. Spontaneous release of acetylcholine from autonomic nerves in the bladder. Br J Pharmacol. 157(4), 607\u2013619 (2009).","journal-title":"Br J Pharmacol."},{"key":"18307_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.11.011","volume":"148","author":"O Lockridge","year":"2015","unstructured":"Lockridge, O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther. 148, 34\u201346 (2015).","journal-title":"Pharmacol Ther."},{"issue":"1","key":"18307_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bjp.0705010","volume":"138","author":"J Minic","year":"2003","unstructured":"Minic, J., Chatonnet, A., Krejci, E. & Molg\u00f3, J. Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions. Br J Pharmacol. 138(1), 177\u2013187 (2003).","journal-title":"Br J Pharmacol."},{"key":"18307_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11910-010-0151-1","volume":"11","author":"V Kumar","year":"2011","unstructured":"Kumar, V. & Kaminski, H. J. Treatment of myasthenia gravis. Current neurology and neuroscience reports. 11, 89\u201396 (2011).","journal-title":"Current neurology and neuroscience reports."},{"key":"18307_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman, G. L., Courtney, K. D., Andres, V. Jr. & Feather-Stone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7, 88\u201395 (1961).","journal-title":"Biochem Pharmacol."},{"key":"18307_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ab.2014.05.031","volume":"462","author":"D Dingova","year":"2014","unstructured":"Dingova, D. et al. Optimal detection of cholinesterase activity in biological samples: modifications to the standard Ellman\u2019s assay. Anal Biochem. 462, 67\u201375 (2014).","journal-title":"Anal Biochem."},{"key":"18307_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72, 248\u2013254 (1976).","journal-title":"Anal Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18307-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:56:44Z","timestamp":1671847004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18307-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["18307"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-18307-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,10]]},"assertion":[{"value":"18 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"304"}}